Alice P. Albright
Directeur Général chez Millennium Challenge Corp.
Postes actifs de Alice P. Albright
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Millennium Challenge Corp. | Directeur Général | 01/02/2022 | - |
Historique de carrière de Alice P. Albright
Anciens postes connus de Alice P. Albright
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Directeur/Membre du Conseil | 31/07/2012 | - |
Statistiques
Internationale
| Etats-Unis | 3 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 2 |
| Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
| Millennium Challenge Corp. | Government |
- Bourse
- Insiders
- Alice P. Albright
- Expérience
